Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Lctx source : Www.biospace.com save search
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
Published: 2024-03-18 (Crawled : 16:00) - biospace.com/
ERNA | $2.15 0.46% 4.8K
|
Information
|
| O: -0.92%
H: 9.26%
C: 8.8%
LCTX | $1.2 -6.98% 0.0% 1M
|
Health Technology
|
| O: -3.88%
H: 1.61%
C: -5.65%
symposium cell therapeutics
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
Published: 2024-03-13 (Crawled : 13:00) - biospace.com/
ERNA | $2.15 0.46% 4.8K
|
Information
|
| O: 4.1%
H: 0.0%
C: -11.81%
LCTX | $1.2 -6.98% 0.0% 1M
|
Health Technology
|
| O: 1.61%
H: 2.38%
C: -3.97%
rg6501 opregen innovation cell therapy results study
RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
Published: 2024-03-11 (Crawled : 17:00) - biospace.com/
ERNA | $2.15 0.46% 4.8K
|
Information
|
| O: 1.17%
H: 10.27%
C: 10.27%
LCTX | $1.2 -6.98% 0.0% 1M
|
Health Technology
|
| O: -5.38%
H: 17.89%
C: 4.88%
rg6501 opregen association research preclinical vision meeting results
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Published: 2024-03-07 (Crawled : 23:00) - biospace.com/
ERNA | $2.15 0.46% 4.8K
|
Information
|
| O: 3.16%
H: 0.0%
C: -0.5%
LCTX | $1.2 -6.98% 0.0% 1M
|
Health Technology
|
| O: 1.77%
H: 0.0%
C: -1.74%
business year update cell therapeutics financial results
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024
Published: 2024-02-29 (Crawled : 15:00) - biospace.com/
LCTX | $1.2 -6.98% 0.0% 1M
|
Health Technology
|
| O: 1.92%
H: 1.89%
C: -1.89%
report business year update cell therapeutics financial results
Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury
Published: 2024-02-13 (Crawled : 14:00) - biospace.com/
LCTX | $1.2 -6.98% 0.0% 1M
|
Health Technology
|
| O: 1.85%
H: 0.83%
C: -7.27%
fda cell treatment clearance
Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering
Published: 2024-02-09 (Crawled : 15:30) - biospace.com/
LCTX | $1.2 -6.98% 0.0% 1M
|
Health Technology
|
| O: 5.56%
H: 0.88%
C: -5.26%
million direct cell offering therapeutics
Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering
Published: 2024-02-06 (Crawled : 15:00) - biospace.com/
LCTX | $1.2 -6.98% 0.0% 1M
|
Health Technology
|
| O: 2.88%
H: 7.48%
C: 3.74%
million direct cell offering therapeutics
Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury
Published: 2023-12-18 (Crawled : 14:00) - biospace.com/
LCTX | $1.2 -6.98% 0.0% 1M
|
Health Technology
|
| O: 1.66%
H: 17.81%
C: 14.57%
drug treatment submission
Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Published: 2023-11-09 (Crawled : 00:00) - biospace.com/
LCTX | $1.2 -6.98% 0.0% 1M
|
Health Technology
|
| O: 0.91%
H: 2.69%
C: -3.6%
business update cell therapeutics financial results
Lineage Cell Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on November 9, 2023
Published: 2023-11-01 (Crawled : 13:00) - biospace.com/
LCTX | $1.2 -6.98% 0.0% 1M
|
Health Technology
|
| O: 0.0%
H: 0.88%
C: -1.75%
report business update cell therapeutics financial results
RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting
Published: 2023-10-24 (Crawled : 12:30) - biospace.com/
LCTX | $1.2 -6.98% 0.0% 1M
|
Health Technology
|
| O: 2.59%
H: 0.84%
C: -0.84%
rg6501 opregen meeting results
Lineage Announces Issuance of U.S. Patent Covering Proprietary Manufacturing and Differentiation Process for Retinal Pigmented Epithelial Cells
Published: 2023-10-11 (Crawled : 13:00) - biospace.com/
LCTX | $1.2 -6.98% 0.0% 1M
|
Health Technology
|
| O: -1.49%
H: 0.76%
C: -3.03%
patent
RG6501 (OpRegen®) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Published: 2023-10-05 (Crawled : 13:30) - biospace.com/
LCTX | $1.2 -6.98% 0.0% 1M
|
Health Technology
|
| O: 1.67%
H: 9.84%
C: 8.2%
rg6501 opregen macular rapid results show
Lineage to Present at Cantor Fitzgerald 2023 Global Healthcare Conference on September 27, 2023
Published: 2023-09-19 (Crawled : 14:00) - biospace.com/
LCTX | $1.2 -6.98% 0.0% 1M
|
Health Technology
|
| O: 0.76%
H: 1.14%
C: -2.27%
conference global
RG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA Congress
Published: 2023-09-13 (Crawled : 12:30) - biospace.com/
LCTX | $1.2 -6.98% 0.0% 1M
|
Health Technology
|
| O: 1.52%
H: 0.74%
C: -2.24%
rg6501 opregen congress results
Lineage to Present at 2023 International Spinal Research Trust Network Meeting
Published: 2023-09-11 (Crawled : 13:00) - biospace.com/
LCTX | $1.2 -6.98% 0.0% 1M
|
Health Technology
|
| O: -2.21%
H: 3.01%
C: 0.0%
international research meeting network trust
Lineage Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Eterna Therapeutics
Published: 2023-09-06 (Crawled : 15:00) - biospace.com/
ERNA | $2.15 0.46% 4.8K
|
Information
|
| O: 5.63%
H: 5.73%
C: -6.14%
LCTX | $1.2 -6.98% 0.0% 1M
|
Health Technology
|
| O: 0.72%
H: 0.72%
C: -2.88%
partnership cell therapeutics
Lineage Cell Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023
Published: 2023-08-03 (Crawled : 13:00) - biospace.com/
LCTX | $1.2 -6.98% 0.0% 1M
|
Health Technology
|
| O: -1.44%
H: 6.57%
C: 2.92%
report business update cell therapeutics financial results
Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer
Published: 2023-07-24 (Crawled : 13:00) - biospace.com/
LCTX | $1.2 -6.98% 0.0% 1M
|
Health Technology
|
| O: 0.0%
H: 0.35%
C: -1.41%
lung report cancer cell treatment research topline therapeutics results study
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.